About Us

Who We Are

Prilenia is a private biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). Our mission is simple but urgent: to develop and provide sustainable access to transformative medicines for people affected by devastating neurodegenerative diseases.   

Prilenia operates across the United States, Canada, Europe and Israel. The company is incorporated in the Netherlands and backed by leading life sciences investors.  

Pridopidine (45 mg twice daily) is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and amyotrophic lateral sclerosis (ALS).

In April 2025, Prilenia and Ferrer entered into a collaboration and license agreement for the commercialization and co-development of pridopidine in Europe and other select international markets. Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific.